BIM 23A760

Drug Profile

BIM 23A760

Alternative Names: BIM23A760; Dopastatin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Class Antineoplastics
  • Mechanism of Action Dopamine receptor agonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acromegaly; Malignant carcinoid syndrome; Neuroendocrine tumours; Pituitary cancer

Most Recent Events

  • 16 Dec 2010 Discontinued - Phase-II for Acromegaly in Europe (SC)
  • 16 Dec 2010 Discontinued - Phase-II for Malignant carcinoid syndrome in Europe (SC)
  • 16 Dec 2010 Discontinued - Preclinical for Neuroendocrine tumours in France (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top